135 related articles for article (PubMed ID: 36931147)
1. European expert panel consensus on the clinical management of BRAF
Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
3. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
5. BRAF
Gourdin G; Chotel L; de la Fouchardière C
Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651
[TBL] [Abstract][Full Text] [Related]
6. Treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract][Full Text] [Related]
7. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
10. Clinical Validation of Plasma-Based Genotyping for
Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
13. Nursing care and management of adverse events for patients with BRAF
Fowler M; Tobback H; Karuri A; Fernández-Ortega P
Support Care Cancer; 2023 Mar; 31(4):204. PubMed ID: 36881161
[TBL] [Abstract][Full Text] [Related]
14. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.
Zeng C; Wang M; Xie S; Wang N; Wang Z; Yi D; Kong F; Chen L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16111-16121. PubMed ID: 37639010
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib plus cetuximab for the treatment of
Ros J; Saoudi N; Baraibar I; Salva F; Tabernero J; Elez E
Therap Adv Gastroenterol; 2022; 15():17562848221110644. PubMed ID: 35812780
[TBL] [Abstract][Full Text] [Related]
16. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Johnson B; Kopetz S
Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic landscape and future direction of metastatic colorectal cancer.
Bando H; Ohtsu A; Yoshino T
Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):306-322. PubMed ID: 36670267
[TBL] [Abstract][Full Text] [Related]
18. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF
Shimozaki K; Hirata K; Sato T; Nakamura M; Kato K; Hirano H; Kumekawa Y; Hino K; Kawakami K; Kito Y; Matsumoto T; Kawakami T; Komoda M; Nagashima K; Sato Y; Yamazaki K; Hironaka S; Takaishi H; Hamamoto Y; Muro K
Clin Colorectal Cancer; 2022 Dec; 21(4):339-346. PubMed ID: 36117091
[TBL] [Abstract][Full Text] [Related]
19. The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1
Mesti T; Rebersek M; Ocvirk J
Radiol Oncol; 2023 Mar; 57(1):103-110. PubMed ID: 36942906
[TBL] [Abstract][Full Text] [Related]
20. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]